<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04316000</url>
  </required_header>
  <id_info>
    <org_study_id>QUALI-BANDING-SET</org_study_id>
    <nct_id>NCT04316000</nct_id>
  </id_info>
  <brief_title>Anxiety and Fear of Cancer Before and After Banding Without Resection in Small SET Management (QUALI-BANDING-SET)</brief_title>
  <official_title>Anxiety, Fear of Cancer and Quality of Life Degree Before and After Endoscopic Band Ligation Without Resection in Subepithelial Tumours of the Digestive Tract ≤15-mm Management: a Multicenter Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Francesc Bas-Cutrina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To analyze the hypothetical improvement in anxiety degree, quality of life and fear of cancer
      in patients diagnosed with a small gastrointestinal subeptithelial tumor when opting for the
      removal of the lesion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This &quot;Quality of Life&quot; study is directly related to the &quot;BANDING-SET&quot; study (NCT03247231),
      whose main aim is to analyze the effectiveness and safety of endoscopic band ligation without
      resection in the small gastrointestinal subepithelial tumours management.

      Using three validated tests (Hospital Anxiety and Depression Scale [HADS], Cancer Worry Scale
      [CWS] and European Five-Dimension Quality of Live test [EuroQol-5D]) patients are evaluated
      before and after the endoscopic procedure.

      Three main groups of patients are presented:

        -  GROUP A, in which the subephitelial tumour is successfully removed [hypothesis: anxiety
           and fear of cancer should decrease].

        -  GROUP B, in which the subephitelial tumour is not successfully removed due to various
           reasons (size &gt;15-mm, not technical success,...) [hypothesis: anxiety and fear of cancer
           shuold be similar before-after].

        -  GROUP C, in which the subephitelial tumour is not observed or is a benign entity, which
           does not require further interventions for these patients [hypothesis: anxiety and fear
           of cancer should decrease].
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Due to SARS-CoV2 (Covid-19) pandemia and its implications for outcomes bias.
  </why_stopped>
  <start_date type="Actual">August 28, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Initial Anxiety degree</measure>
    <time_frame>1-2 months</time_frame>
    <description>At 1-2 months, number of patients with a total anxiety score of 8 or more points in the Hospital Anxiety and Depression Scale (HADS), anxiety subescale.
Hospital Anxiety and Depression Scale (HADS), anxiety subescale, legend:
0-7 points: Normal.
8-10 points: Borderline anxiety.
11-21 points: Anxiety disorder.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Initial Fear of Cancer degree</measure>
    <time_frame>1-2 months</time_frame>
    <description>At 1-2 months, number of patients with a total fear of cancer score of 11 or more points in the Cancer Worry Scale (CWS).
Cancer Worry Scale (CWS) legend:
6-10 points: Low.
11-15 points: Moderate.
16-20 points: High.
21-24 points: Very high.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Long-term Anxiety degree</measure>
    <time_frame>1 year</time_frame>
    <description>At 1 year, number of patients with a total anxiety score of 8 or more points in the Hospital Anxiety and Depression Scale (HADS), anxiety subescale.
Hospital Anxiety and Depression Scale (HADS), anxiety subescale, legend:
0-7 points: Normal.
8-10 points: Borderline anxiety.
11-21 points: Anxiety disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term Fear of Cancer degree</measure>
    <time_frame>1 year</time_frame>
    <description>At 1 year, number of patients with a total fear of cancer score of 11 or more points in the Cancer Worry Scale (CWS).
Cancer Worry Scale (CWS) legend:
6-10 points: Low.
11-15 points: Moderate.
16-20 points: High.
21-24 points: Very high.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Gastrointestinal Subepithelial Tumors</condition>
  <arm_group>
    <arm_group_label>A - Removal of the Subepithelial Tumour</arm_group_label>
    <description>The subephitelial tumour is successfully removed by endoscopic band ligation without resection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Non Removal of the Subepithelial Tumour</arm_group_label>
    <description>The subephitelial tumour is not successfully removed due to various reasons (size &gt;15-mm, not technical success,...).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C - Not Observed or Benign Subepithelial Tumour</arm_group_label>
    <description>The subephitelial tumour is not observed or is a benign entity, which does not require further interventions for these patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Initial Anxiety and Fear of Cancer Test</intervention_name>
    <description>Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) before the initial endoscopic procedure.</description>
    <arm_group_label>A - Removal of the Subepithelial Tumour</arm_group_label>
    <arm_group_label>B - Non Removal of the Subepithelial Tumour</arm_group_label>
    <arm_group_label>C - Not Observed or Benign Subepithelial Tumour</arm_group_label>
    <other_name>Initial Test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic band ligation without resection of the subpetihelial tumour.</intervention_name>
    <description>Correct application of the elastic band in the subepithelial tumor, achieving its removal by self-amputation in the 4-6 weeks endoscopic ultrasonography (EUS) control.</description>
    <arm_group_label>A - Removal of the Subepithelial Tumour</arm_group_label>
    <other_name>Successful SET banding</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1-2 Months Anxiety and Fear of Cancer Test</intervention_name>
    <description>Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1-2 months of the initial endoscopic procedure, knowing whether the tumor has either been removed or not, is a benign entity or has not been observed.</description>
    <arm_group_label>A - Removal of the Subepithelial Tumour</arm_group_label>
    <arm_group_label>B - Non Removal of the Subepithelial Tumour</arm_group_label>
    <arm_group_label>C - Not Observed or Benign Subepithelial Tumour</arm_group_label>
    <other_name>1-2 Months Test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1 Year Anxiety and Fear of Cancer Test</intervention_name>
    <description>Answer to Hospital Anxiety and Depression Scale (HADS), Cancer Worry Scale (CWS) and European Five-Dimension Quality of Live test (EuroQol-5D) after 1 year of the initial endoscopic procedure, knowing whether the tumor has either been removed or not.</description>
    <arm_group_label>A - Removal of the Subepithelial Tumour</arm_group_label>
    <arm_group_label>B - Non Removal of the Subepithelial Tumour</arm_group_label>
    <other_name>1 Year Test</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with subepithelial lesions (SEL) in the gastrointestinal tract.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Age between 18 and 80 years.

          -  Patient able to sign and understand the Informed Consent.

          -  Patient with a previously corroborated diagnosis of a subepithelial tumor (SET) by
             previous endoscopic ultrasonography (EUS), or possible diagnosis of SET by finding a
             subepithelial lesion (SEL) in a conventional endoscopy performed that will require a
             EUS study.

          -  Acceptance by the patient as a candidate of the BANDING-SET study (NCT03247231) of
             assessment of the effectiveness and safety of band ligation without resection of
             subepithelial tumors of the digestive tract ≤15-mm, with the prior signing of the
             Informed Consent of this study.

          -  Patient that understand the concept of the study and will complete all the time frame
             until the study end

        EXCLUSION CRITERIA:

          -  No Informed Consent.

          -  No BANDING-SET study (NCT03247231) Informed Consent.

          -  Patients with functional diversity, unable to understand the nature and possible
             consequences of the study.

          -  Patients unable to maintain subsequent follow-up (lack of adherence).

          -  Patients with a life expectancy of less than 12 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Francesc Bas-Cutrina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endoscopy Unit; Digestive Diseases Department; H. Universitari de Bellvitge.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joan B Gornals, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endoscopy Unit; Digestive Diseases Department; H. Universitari de Bellvitge.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sebastià Videla, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology; H. Universitari de Bellvitge.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Germans Trias i Pujol (Can Ruti)</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona, Catalonia</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona, Catalonia</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Mútua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona, Catalonia</state>
        <zip>08221</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Pau i de la Santa Creu</name>
      <address>
        <city>Barcelona</city>
        <state>Catalonia</state>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Girona Doctor Josep Trueta</name>
      <address>
        <city>Girona</city>
        <state>Catalonia</state>
        <zip>17007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Arnau de Vilanova de Lleida</name>
      <address>
        <city>Lleida</city>
        <state>Catalonia</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Joan XXIII de Tarragona</name>
      <address>
        <city>Tarragona</city>
        <state>Catalonia</state>
        <zip>43005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983 Jun;67(6):361-70.</citation>
    <PMID>6880820</PMID>
  </results_reference>
  <results_reference>
    <citation>Herdman M, Badia X, Berra S. [EuroQol-5D: a simple alternative for measuring health-related quality of life in primary care]. Aten Primaria. 2001 Oct 15;28(6):425-30. Spanish.</citation>
    <PMID>11602124</PMID>
  </results_reference>
  <results_reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76.</citation>
    <PMID>8433390</PMID>
  </results_reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2020</study_first_posted>
  <last_update_submitted>May 2, 2020</last_update_submitted>
  <last_update_submitted_qc>May 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Francesc Bas-Cutrina</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Tumourophobia</keyword>
  <keyword>Anxiety for Cancer</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Cancer Worry Scale (CWS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

